Big Pharma
2 October 2025 From stalled drug approvals to suspended patent investigations, US rightsholders face mounting uncertainty during the federal freeze.
26 September 2025
23 September 2025
23 September 2025
22 September 2025
Latest Features
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.
Biotechnology
Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
Americas
With growing legislation, research and demand for medical use, cannabis presents an economic opportunity for the Caribbean—but IP rights in the region have some way to go, write Keesha Fleming Lake of Keesha Fleming Lake, and Rachael Lodge Corrie of Foga Daley.
Americas
A patent fee structure being mooted in the US could hurt the innovation economy, especially in industries like biotech and pharma—and will face backlash from businesses, writes Paul Hunter of Foley.
Europe
A new law affecting disputes concerning the ‘Bolar provision’ could allow competitors to enter the Ukrainian market before a patent expires, explains Volodymyr Hrunskyi of Sayenko Kharenko.
Americas
Smaller US companies can now choose to take on much larger, foreign opponents at the ITC, explain Cristen Corry, Paul Ainsworth and Uma Everett of Sterne Kessler.
Americas
Will this year be defined by a concerted shift towards ‘One Health’? Simon Kiddle and Rebecca Tollervey of Mewburn Ellis explore.
More News
18 September 2025 At AIPPI’s World Congress 2025, a panel explored how personalised medicine is pushing patent law into new territory, and why harmonisation remains a distant goal.
18 September 2025 The exodus of patent trial litigators was ‘an easy choice’ due to their new employer’s ‘scale, vision and entrepreneurial culture’.
17 September 2025 A notable Ninth Circuit ruling raises questions about disclosure that trade secrets plaintiffs will want to consider—particularly with regards to timing, says Carolyn Hoecker Luedtke of Munger, Tolles & Olson.
16 September 2025 From drug discovery to post-market surveillance, AI is rewriting the rules in pharma—and the patent system is struggling to keep up. At AIPPI’s World Congress 2025, Marisa Woutersen hears experts debate AI disclosure, inventive step, and inventorship.
11 September 2025 Deal resolves just one case in Regeneron’s roll-call of actions against competitors looking to launch versions of a $6bn-a-year blockbuster eye-disease treatment.
9 September 2025 Federal oversight, funding cuts, and patent uncertainties are forcing universities, startups, and pharma companies to reassess partnership models, finds Marisa Woutersen.
5 September 2025 The UK pharma giant has opened a new front in its global litigation strategy involving Moderna, Pfizer, and BioNTech.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox